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Abstract Epistaxis is a very common ENT event. Apart
from the effectiveness of the different treatment options,
the discomfort and the financial burden are of great
importance. It has been the aim of this study to obtain data
regarding the discomfort/pain of the epistaxis treatments
and to calculate the financial burden. During the period
between April 2010 and July 2011 epistaxis patients at our
hospital had the opportunity to rate the discomfort/pain
they experienced during their treatment on a 0–10 VAS
scale. The costs of epistaxis treatments were calculated in
an extended cohort. 84 VAS scores in 61 patients were
acquired and the costs of treatment were calculated in 96
patients. The lowest VAS scores were found in chemical
and electric coagulation with 1.5 and 2.0, respectively,
followed by surgery (3.0), Rapid Rhino packing (6.0) and
balloon pack (7.5). The costs of treatments depended on
whether the treatment was in an out- or inpatient setting.
Surgery was not significantly more expensive than packing
methods in the inpatient setting. Anterior epistaxis could be
managed by local coagulation with an acceptable impact/
cost ratio. At our institution, surgery was the most cost
effective and the least troublesome procedure in posterior
bleedings, preceded by Rapid Rhino packing if required.
Keywords Epistaxis  Treatment  Discomfort 
Pain  Costs  Surgery
Introduction
Epistaxis is a common event within the general population.
It has been stated that up to 60 % of the general population
experiences at least once an episode of epistaxis and 6 % of
people with epistaxis require medical attention [1]. Due to
its mainly self-limiting course, it is often considered a
minor medical event and yet it represents the most frequent
rhinologic emergency [2]. Epistaxis is commonly divided
into anterior and posterior bleedings depending on whether
the source is visible upon anterior rhinoscopy. Several
treatment options are available, depending upon the loca-
tion of the bleeding source. Although the anatomy of each
nose, the cause of epistaxis and the coexisting medical
conditions can widely vary, there have been efforts to
establish therapeutic algorithms and attempts to standardise
epistaxis treatment at many institutions. There is only
scarce literature available that compares the pain that dif-
ferent treatment options cause [3–7].
As with many other acute and chronic diseases, pain
plays a major role in profiling the compliance of a patient
and thus affecting improvement of the condition of the
patient. Patients who are satisfied with their improvement
are more compliant with treatment recommendations [8].
Administrative and overall health care costs show a
consistent increase over the years [9]; and as competition in
the health care sector increases, the pressure on hospitals to
reduce overall costs also increases [10]. Cost effectiveness
in health care could also protect from phenomena like
medical bankruptcy [11].
Knowing the pain and cost of epistaxis treatment and
matching them with existing data about the efficacy of each
treatment, we may be able to suggest our department that
an epistaxis treatment model is effective, less painful and
economical [12].
G. Nikolaou (&)  D. Holzmann  M. B. Soyka
Department of Otorhinolaryngology, Head and Neck Surgery,
University Hospital, Frauenklinikstrasse 24,
8091 Zu¨rich, Switzerland
e-mail: georgios.nikolaou@usz.ch
123
Eur Arch Otorhinolaryngol (2013) 270:2239–2244
DOI 10.1007/s00405-012-2339-2
Materials and methods
Study
The study was conducted prospectively in accordance with
the latest version of the Helsinki declarations. The protocol
was approved by the local ethics committee and review
board.
Treatment
Our hospital is a tertiary referral centre dealing with almost
600 epistaxis’ patients annually. Each patient referred to
our hospital with epistaxis was first examined in our
ambulatory care unit. The treatment each patient received
was in accordance to the treatment algorithm previously
published [12]. This involves an initial treatment of less
invasive options which can be expanded depending on
efficacy. If the conservative treatments fail, patients are
kept in hospital and surgical therapy is considered.
Prior to packing and cautery, we anaesthetize the nose
using oxybuprocaine spray or cotton pledgets soaked in
oxybuprocaine. All patients received the same local
anaesthesia. For the treatment of anterior epistaxis electric
or chemical cautery was the treatment of choice and seldom
was a pack used. For posterior epistaxis, an inflatable Rapid
Rhino packing was used (7.5 cm anterior–posterior, ENT
Arthrocare Europe, Stockholm, Sweden). In cases where
bleeding cannot be controlled by the above mentioned
method, a Foley catheter is used and is inserted through the
nose until the epipharynx is reached, where it is then
inflated and the nasal cavity is packed with fatty-gauze.
Patients with Rapid Rhino packing were treated either in
an in- or outpatient setting. Patients who were hemody-
namically unstable or had no good bleeding control with
packing or received Foley catheter packing were treated in
an inpatient setting. If this measure is not able to control
bleeding a transnasal sphenopalatine artery closure is per-
formed with diathermy and/or external ligation of the eth-
moidal arteries under general anaesthesia [13]. At the end of
each treatment, patients were asked to provide information
about the levels of discomfort they experienced, with
regards to the procedure that they had undergone.
Patients
Patients who were treated for epistaxis, either as outpa-
tients or inpatients, were included in the period between
April 2010 and July 2011. Bleedings secondary to trauma
or caused by hereditary haemorrhagic telangiectasia
(M. Osler) were excluded.
The following information was collected for each
patient: age, sex, type of bleeding (i.e. anterior/posterior),
type of treatment and visual analogue scale score for the
evaluation of pain (VAS score). Costs were calculated for
each treatment or treatment combination.
Discomfort/pain
A VAS questionnaire was handed out to all patients, who
were treated for epistaxis.
84 VAS scores in 61 patients were acquired. The
patients were asked to record the discomfort experienced
on a 10-cm 11-point VAS scale (0: no pain, 10: most severe
pain imaginable) for each treatment they received. If the
patient underwent more than one treatment, each event was
analysed separately. The evaluation form was handed out
to the outpatients after the end of each treatment. With
regards to patients who received packing, the levels of
discomfort during insertion, remaining or removal of the
device were not distinguished.
Costs
Costs of treatment were calculated in 96 patients. For all
patients that provided VAS data, costs were calculated in
accordance to the cost calculating system used in our
institution. Because of the small number of treatments in
some subgroups, we additionally calculated the treatment
costs of a number of patients from our previous study to
increase case load for the different treatments [12].
For the outpatients, the costs of epistaxis treatment were
calculated based on the actual time, type of treatment and
material used. This includes physical examination, the use of
an electrocautery device and potential further visits i.e. for the
removal of packing. Costs of all packing material were also
included. Generally, patients without packing did not undergo
any further visits. Patients with packing had a follow-up visit
for the removal of the packing and endoscopy of the nose.
For inpatients, the costs were calculated on the basis of a
fixed rate plus a daily charge, depending on the length of
the stay. In this formula all medical accomplishments and
services are included. No additional costs were charged for
separate medical investigations/treatments or surgery.
Follow-up costs for inpatients were included, as for the
outpatients, in the overall costs.
Statistics
Two primary endpoints were defined as the total costs of
each treatment and pain/discomfort score experienced by
the patient. Median values and 95 % confidence intervals
are provided for both the cost and VAS analyses. Com-
parison between treatment groups was accomplished by
Mann–Whitney testing. Comparison between two VAS
ratings for the same patient were analysed by the Wilcoxon
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matched-pairs signed rank test. The significance level alpha
was set to 0.05.
Results
The costs of treatment were calculated for the cases of 96
patients and the results can be found in Table 1.
A significant difference resulted in the costs between
electric cautery, chemical coagulation and Rapid Rhino on
the one hand and all other treatment combinations on the other
hand as it can be viewed in Fig. 1. Bipolar coagulation along
with chemical coagulation and Rapid Rhino packing showed
the lowest costs whereas there is a increase in costs for the
latter depending on the use in an out- or inpatient setting.
All therapy options used in the inpatient setting showed
much higher costs with a smaller spread. The costs for
these therapies depended on the duration of hospitalisation.
84 VAS scores from 61 patients were acquired. The male
to female ratio was 5:3 with a median age of 72 years (range
18–89), while 45 patients had anterior whereas 16 were
found to have posterior epistaxis. The provided VAS scores
are shown in Table 2. There was no significant difference in
the VAS scores (p = 0.7) between the treatment options that
were used for anteriorly located bleeding sources (Fig. 2).
Amongst treatment options for posterior located bleed-
ing sources, there was a wide spread of VAS scores, with a
statistically significant difference between Rapid Rhino
packing and surgery (p = 0.03) and between the balloon
packing and surgery (p = 0.02).
From those patients who required both packing and
surgery, a separate rating was obtained following both
treatments resulting in a time-dependent paired analysis
shown in Fig. 3. A significantly lower discomfort value is
presented in the direct comparison (p = 0.02).
Discussion
The ideal treatment for epistaxis should have three char-
acteristics: low-discomfort, cost effectiveness and low
level of recurrences. The results indicate the differences in
discomfort and pain between the various treatment groups.
Surgery not only is less troublesome to the patient, but also
does not increase the costs of treatment.
Table 1 Median costs in Swiss
Francs are provided along with
upper and lower confidence
intervals and number of
treatments
Treatment Total no (n = 96) Costs median (95 % CI)
Bipolar coagulation 36 185.6 (173.2, 209.6)
Chemical coagulation 6 203.0 (159.8, 257.6)
Rapid Rhino packing 17 335.6 (834.2, 5,653)
Rapid Rhino packing ? surgery 10 10,309 (9,872, 11,823)
Rapid Rhino packing ? balloon packing 5 10,160 (9,123, 11,197)
Rapid Rhino packing ? balloon packing ? surgery 5 10,160 (8,463, 14,806)
Balloon packing 5 10,995 (9,479, 11,843)
Balloon packing ? surgery 6 10,192 (8,680, 12,517)
Surgery 6 10,269 (9,407, 10,986)
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Fig. 1 Costs in Swiss Francs (CHF) for each treatment and
combination. Significant differences are indicated (* p \ 0.05 and
** p \ 0.01)
Table 2 Median VAS scores are provided along with upper and
lower confidence intervals and number of treatments
Treatment Total no (n) Median VAS score (95 % CI)
Chemical coagulation 14 1.5 (1.45, 3.98)
Bipolar coagulation 40 2.0 (2.26, 3.78)
Rapid Rhino packing 15 6.0 (4.18, 7.16)
Surgery 11 3.0 (1.8, 4.93)
Balloon packing 4 7.5 (3.71, 11.29)
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Limitations of the study
While using a prospective approach, we believe that the
relatively low caseload poses potential limitations in the
study of treatment costs. To overcome this source of bias
and to increase the validity of our cost analysis, we
additionally calculated the costs of a number of treatments
from our previously published retrospective study.
Anterior epistaxis
According to the results of this study, it can be stated that
anterior epistaxis can be treated with either electric or
chemical coagulation causing no significant differences in
discomfort and with similar economic burden.
It is known from previous investigations that chemical
coagulation is more prone to failure [12]. From this point
of view, we conclude that it would be better to treat an
anterior epistaxis with electrocautery, if possible, as all
treatment failures lead to increased costs and repetitive
discomfort.
Posterior epistaxis
Amongst the treatment options available for posterior epi-
staxis, there are significant differences in the VAS scores. The
lowest median VAS score was caused by surgery, followed
by Rapid Rhino and balloon packing. It has been shown that
the majority of patients with nasal packing can be safely
managed in an outpatient setting [14]. In a previous study,
discomfort upon insertion or removal of Rapid Rhino or
Merocel was assessed and a significant difference, with Rapid
Rhino causing less discomfort on insertion or removal, has
been shown [5]. There are also a number of studies showing
that the discomfort caused by Rapid Rhino is less than for
other nasal packing methods not used in our study [4–7].
There is no doubt that a skilled surgeon is required to perform
sphenopalatine artery closure. And yet, in many hospitals
around the world efforts are made to treat patients with pos-
terior bleeding primarily with surgery instead of conservative
treatment [15, 16]. Complications seen by the use of packing
further support our belief that surgical treatment is better in
managing posterior epistaxis.
Regarding the economic burden that treatment options
for posterior epistaxis cause, there is no significant differ-
ence between Rapid Rhino surgery and the balloon
packing. A wide range of costs within the Rapid Rhino
treated group and a large difference between anterior and
posterior treatments have been recorded. This fact is caused
by the different requirements to hospitalise a patient. While
Rapid Rhino can be used safely in an outpatient setting as
long as the bleeding is well controlled and the patient’s
general condition allows the discharge, other treatments
might require an in-hospital stay. As shown in our previous
study, surgery has significantly fewer failures than packing
[12]. In a review of transnasal sphenopalatine artery
occlusions, either through ligation or diathermy, the overall
success rate to control bleeding ranged from 92 to 100 %
with a mean of 98 %. The literature suggests higher
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Fig. 2 Visual analogue scale scores for different treatments. Signi-
ficant differences are indicated (* p \ 0.05, ** p \ 0.01)
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Fig. 3 Patients who received both treatments (packing and surgery)
and who rated both treatments showed significantly less discomfort by
the surgical treatment. Results from Wilcoxon matched-pairs rank test
n = 8
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success rates if the sphenopalatine artery ligation is per-
formed simultaneously with anterior ethmoidal artery
ligation [16].
The major parameter that plays a role in cost calculation
is the duration of the hospitalisation and this has been
shown to be shorter for surgery than for nasal packing [15].
For posterior epistaxis, the costs, when comparing sur-
gery with the other treatment options are not different.
According to our cost analysis surgical treatment is not as
expensive as assumed; this is in concordance with other
studies [12, 15, 17].
Former studies stated that nasal packing has signifi-
cantly lower hospital charges than surgery or intraarterial
embolisation and patients who did not come to operation
had fewer complications, a shorter hospital stay, and lower
costs [18, 19]. One limitation of our study has been the use
of the local cost calculating system. Although other health
care systems could come to other calculations, our results
are fully in concordance with current literature that showed
lower costs and better success of surgery when used as first
line treatment in posterior epistaxis [15]. Two studies that
were performed in 2004 and 2006 have shown that there
are highly significant differences between surgery and
packing not only regarding the efficacy but also the dura-
tion of hospital stay and the cost reduction [20, 21].
Intraarterial embolization has not been included in our
treatment options due to the limited number of interven-
tions in Zurich during the study period. A recent study
about arterial embolization in the management of posterior
epistaxis has shown ability to control bleeding in acute
setting of 88 % comparable with older reports but arterial
embolization requires a well-organised setting and skilled
interventional radiologists. The risks of these procedures
like cerebrovascular accidents although small should be
taken into account [22]. Miller and Stevens [23] described
that there was no economic advantage for angiography
compared with transnasal endoscopic sphenopalatine artery
ligation.
Combining our results while looking at the treatment
failures of the different treatment options of an antecedent
study (Fig. 4), it can be easily concluded that balloon
packing is expensive, prone to failure and causes the most
discomfort to patients.
Conclusion
According to the VAS scores obtained and costs calculated
within the context of recurrences, the best treatment option
for posterior epistaxis appears to be a temporary packing
with a Rapid Rhino nasal pack and consecutive surgery.
With these option two therapies with a relatively low
VAS-discomfort score are used, the costs are similar to
other combinations used in the inpatient setting and
recurrences are infrequent. Local cautery seems to be the
therapy of choice in anterior bleedings. Our findings further
support the idea of training young otolaryngologists to
become skilled endonasal surgeons to control nosebleeds
surgically.
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